Procter & Gamble (PG) to Terminate Pact with Curis (CRIS)
Tweet
Share
E-mailGet Alerts CRIS Hot Sheet
Up)Join SI Premium – FREE
In Today's 8-K Filing From CURIS (Nasdaq: CRIS): On September 18, 2005, Curis, Inc. entered into a Collaboration, Research and License Agreement with Procter & Gamble, Inc. and Procter & Gamble Pharmaceuticals, a division of The Proctor & Gamble Company (NYSE: PG), to evaluate and seek to develop potential treatments for hair growth regulation and skin disorders utilizing the Company's Hedgehog agonist technology.
Under the terms of the Agreement, the Company granted to P&G an exclusive, worldwide, royalty-bearing license for the development and commercialization of topical dermatological and hair growth products that incorporate the Company's Hedgehog agonist technology.
...On May 9, 2007, however, P&G notified the Company of P&G's decision to terminate the Agreement due to P&G's belief that the topically-applied Hedgehog agonist compounds that were being developed under the Agreement did not exhibit an acceptable safety profile to warrant further development. The effective date of termination of the Agreement is six months from the date of notice, or November 9, 2007.
On the termination date of November 9, 2007, all licenses granted to P&G by the Company shall terminate. The Company shall have the exclusive option to acquire from P&G (with the right to license or sublicense) all data generated by P&G and other similar information and items related to the compounds developed during the collaboration by P&G, on commercially reasonable terms to be mutually agreed to by the parties.
Under the terms of the Agreement, the Company granted to P&G an exclusive, worldwide, royalty-bearing license for the development and commercialization of topical dermatological and hair growth products that incorporate the Company's Hedgehog agonist technology.
...On May 9, 2007, however, P&G notified the Company of P&G's decision to terminate the Agreement due to P&G's belief that the topically-applied Hedgehog agonist compounds that were being developed under the Agreement did not exhibit an acceptable safety profile to warrant further development. The effective date of termination of the Agreement is six months from the date of notice, or November 9, 2007.
On the termination date of November 9, 2007, all licenses granted to P&G by the Company shall terminate. The Company shall have the exclusive option to acquire from P&G (with the right to license or sublicense) all data generated by P&G and other similar information and items related to the compounds developed during the collaboration by P&G, on commercially reasonable terms to be mutually agreed to by the parties.
You May Also Be Interested In
- UPDATE: Gaming and Leisure Properties (GLPI) to Acquire Real Property Assets of Bally's (BALY) Two Rhode Island Assets for $1 Billion
- GrafTech (EAF) Announces Appointment of Marcel Kessler as CEO and President
- Adial Pharmaceuticals (ADIL) CEO Issues Letter to Shareholders
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
